DESITIN PHARMA A/S: Financial statements 2026
CVR: 19389006
Source: annual report 2026, Danish Business Authority
01/10/2025 – 30/09/2026
DESITIN PHARMA A/S (CVR 19389006) has filed annual accounts for 2026. In 2026, the company reported a gross profit of DKK 3,230,179 and a net result of DKK 350,332 compared with DKK 288,733 the year before. That is an increase of 50.1% compared with the year before. Equity in the 2026 report amounted to DKK 7,394,472. The solvency ratio was 88.9%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 3,230,179
- Profit/Loss
- DKK 350,332
- Equity
- DKK 7,394,472
- Total Assets
- DKK 8,318,592
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2026 | - | 3.2M | 350K | 7.4M | 2 |
| 2025 | - | 2.2M | 289K | 7M | 2 |
| 2024 | - | 2.1M | 286K | 6.8M | 2 |
| 2023 | - | 3M | 2.6M | 8.6M | 2 |
| 2022 | - | 3.5M | 346K | 6.4M | 2 |
Official annual report
Find more companies like DESITIN PHARMA A/S
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2026
DESITIN PHARMA A/S has won the tender "Amgros 2027 1.615.b" issued by Amgros I/S worth 67,284,330 DKK.
Contact info changed: new phone: 33730073, new email: [email protected] (August 11, 2026).
As of August 6, 2026, Oliver Christoph has joined the board of directors of DESITIN PHARMA A/S.
As of August 6, 2026, Katrin Elisabeth Thieken has left the board of directors of DESITIN PHARMA A/S.
About DESITIN PHARMA A/S
DESITIN PHARMA A/S is a Danish company of the type Aktieselskab based in København V, founded in 1996. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Eli Lønne. The board consists of Philipp Andreas Bloching (chair), Eli Lønne and Oliver Christoph. The company is owned by Desitin Arzneimittel GmbH. The company has 1 employee (2026). In 2026, the company reported a gross profit of DKK 3,230,179 and a net result of DKK 350,332 compared with DKK 288,733 the year before. Equity in the 2026 report amounted to DKK 7,394,472.